Anirban Maitra

This study identifies KRAS-driven metabolic reprogramming through MFSD2A-mediated lysophosphatidylcholine scavenging as a driver of PDAC progression and shows that targeting this pathway with edelfosine has anti-cancer effects.

This study identifies AXL as a driver of adaptive resistance to KRAS inhibition and shows that combining AXL and KRAS inhibition improves tumor control and immune response in lung and pancreatic cancer models.

The paper identifies four epithelial transcription states in pancreatic cancer and links their origins to early developmental processes.

This study uses AI-driven proteomics to identify molecular transitions in pancreatic cancer precursors, revealing early molecular changes in histologically normal tissue.

STAPLE automates spatial transcriptomics analysis by integrating multiple tools into a modular framework and provides AI-driven interpretation of results.

UniST reconstructs dense 3D spatial transcriptomics data from sparse serial sections, restoring structural continuity and biologically meaningful expression patterns in multiple tissue contexts.

The paper identifies multi-omic phenotypes in pancreatic precursor lesions to distinguish progressive from indolent precancers using integrative transcriptomic, genomic, and spatial data.

PoweREST estimates statistical power for detecting differentially expressed genes in spatial transcriptomics experiments using 10X Genomics Visium data.

This study identifies the YAP1-SDC1 axis as a driver of resistance to mKRAS inhibitors in gastrointestinal cancers and suggests targeting this axis to overcome resistance.

This study identifies cellular and microenvironmental factors contributing to radiation therapy resistance in pancreatic cancer using spatial transcriptomics and single-cell RNA sequencing.

PIVOT is an open-source tool for nonlinear registration of multi-omic spatial data, demonstrating improved throughput compared to existing workflows.

This study identifies small molecule Kras inhibitors that synergize with anti-CTLA4 therapy to reprogram Tregs and enhance immunotherapy efficacy in PDAC.

This study investigates how CDK8 remodels the tumor microenvironment to resist KRASG12D inhibition in PDAC, showing that targeting CDK8 can overcome resistance and improve survival.

This study shows that ATRA causes ADAR1 degradation and enhances PD-1 blockade to improve antitumor immunity and survival in pancreatic cancer.

This study shows that mutant GNAS drives a gastric metaplasia gene signature and glycolytic dependency in IPMNs, offering a therapeutic target.

This study evaluates combinations of PDAC biomarkers across multiple labs, finding improved sensitivity and specificity for early-stage detection compared to CA19-9 alone.

The paper develops TimiGP-Response to analyze the tumor immune microenvironment's association with immunotherapy response across multiple cancer types and identifies key immune cell interactions linked to treatment outcomes.

This study identifies GNASR201C as a driver of pyloric metaplasia in IPMN, characterized by tumor-suppressive glycans that inhibit cancer progression.

The paper quantifies tumor-specific total mRNA expression from bulk data and shows its association with clinical outcomes across 15 cancer types.

The paper examines the expression of ACE2 and TMPRSS2 in single-cell RNA sequencing datasets from different parts of the gastrointestinal tract to assess SARS-CoV-2 entry potential in enterocytes.

The paper identifies tissue morphology biomarkers in long-term PDAC survivors using digital pathology and machine learning, finding reduced heterogeneity and extra-tumoral space features correlate with better survival.